© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 20, 1733-1737,
October 20, 1999
© 1999 Oxford University Press
Prostate-Specific Antigen Testing of Older Men
Affiliations of authors: H. B. Carter, P. K. Landis (Department of Urology), L. A. Fleisher (Department of Anesthesiology), The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD; E. J. Metter, Gerontology Research Center, National Institute on Aging, Baltimore; J. D. Pearson, Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, and Department of Epidemiology, Merck Research Laboratories, Blue Bell, PA.
Correspondence to: H. Ballentine Carter, M.D., Department of Urology, 403 Marburg, The Johns Hopkins Hospital, 600 N. Wolfe St., Baltimore, MD 21287-2101 (e-mail: hcarter{at}jhmi.edu).
BACKGROUND: Elevated serum prostate-specific antigen (PSA) levels are predictive of a future diagnosis of prostate cancer. To test the hypothesis that older men with low PSA levels may require less intensive PSA testing because of a reduced prostate cancer detection rate, we evaluated the association between age, baseline PSA level, and prostate cancer detection. METHODS: We conducted a prospective cohort study among participants in a study of aging who had serial PSA measurements taken from age 60 or 65 years until they either were diagnosed with prostate cancer (cancer case subjects) or reached the age of 75 years (subjects without prostate cancer). The time of cancer detection among cancer case subjects was defined as the measurement date on which a PSA level above 4.0 ng/mL was detected (i.e., PSA conversion). Cancer case subjects and subjects without prostate cancer were analyzed according to baseline PSA level and age. RESULTS: All cancer case subjects in the 60-year-old cohort had baseline PSA levels above 0.5 ng/mL, and 14 of 15 cancer cases that would have been detected by a PSA conversion among the 65-year-old cohort were associated with baseline PSA levels of 1.1 ng/mL or more. If PSA testing were discontinued in men aged 65 years with PSA levels of 0.5 ng/mL or less, 100% (95% confidence interval [CI] = 78%-100%) of the cancers would still be detected by age 75 years; if PSA testing were discontinued in men aged 65 years who had PSA levels of 1.0 ng/mL or less, 94% (95% CI = 70%-100%) of the cancers would still be detected by age 75 years. CONCLUSIONS: These data suggest that a decrease in the intensity of screening among older men with low PSA values may not lead to an increase in undetected prostate cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Lilja, D. Ulmert, T. Bjork, C. Becker, A. M. Serio, J.-A. Nilsson, P.-A. Abrahamsson, A. J. Vickers, and G. Berglund Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years J. Clin. Oncol., February 1, 2007; 25(4): 431 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Kuller, A. Thomas, G. Grandits, and J. D. Neaton Elevated Prostate-Specific Antigen Levels Up to 25 Years Prior to Death from Prostate Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 373 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lu-Yao, T. A. Stukel, and S.-L. Yao Prostate-Specific Antigen Screening in Elderly Men J Natl Cancer Inst, December 3, 2003; 95(23): 1792 - 1797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Matsumoto Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M76 - 99. [Full Text]
|
|